David Y. Oh

4.1k total citations · 2 hit papers
43 papers, 2.4k citations indexed

About

David Y. Oh is a scholar working on Oncology, Immunology and Surgery. According to data from OpenAlex, David Y. Oh has authored 43 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 21 papers in Immunology and 7 papers in Surgery. Recurrent topics in David Y. Oh's work include Cancer Immunotherapy and Biomarkers (26 papers), CAR-T cell therapy research (14 papers) and Immunotherapy and Immune Responses (14 papers). David Y. Oh is often cited by papers focused on Cancer Immunotherapy and Biomarkers (26 papers), CAR-T cell therapy research (14 papers) and Immunotherapy and Immune Responses (14 papers). David Y. Oh collaborates with scholars based in United States, Canada and Australia. David Y. Oh's co-authors include Lawrence Fong, Judy Lieberman, Zusen Fan, Paul J. Beresford, Dong Zhang, Richard S. Lewis, Nirav R. Bhakta, Serena S. Kwek, Li Zhang and Jason Cham and has published in prestigious journals such as Cell, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

David Y. Oh

40 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer

2020 464 citations David Y. Oh, Serena S. Kwek et al. Cell profile →
Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox

2021 273 citations David Y. Oh, Lawrence Fong profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Y. Oh United States	18	1.1k	1.0k	918	299	231	43	2.4k
Anna E. Vilgelm United States	23	630 0.6×	1.0k 1.0×	773 0.8×	283 0.9×	171 0.7×	48	1.9k
Tomohide Tsukahara Japan	29	1.0k 0.9×	1.2k 1.2×	982 1.1×	458 1.5×	152 0.7×	118	2.4k
Sophie E. Acton United Kingdom	16	1.8k 1.6×	1.2k 1.2×	623 0.7×	181 0.6×	226 1.0×	26	3.0k
Tomonori Yaguchi Japan	28	912 0.8×	989 1.0×	687 0.7×	281 0.9×	102 0.4×	70	2.0k
Adrienne Luoma United States	20	1.8k 1.6×	1.4k 1.4×	902 1.0×	194 0.6×	150 0.6×	25	3.0k
Jennifer L. Guerriero United States	19	1.2k 1.1×	1.2k 1.1×	1.0k 1.1×	249 0.8×	136 0.6×	50	2.5k
Giulia Parisi Italy	21	1.4k 1.3×	1.5k 1.5×	1.1k 1.2×	323 1.1×	107 0.5×	35	2.8k
Yasuto Akiyama Japan	27	708 0.6×	937 0.9×	878 1.0×	270 0.9×	122 0.5×	128	2.2k
Eszter Lázár‐Molnár United States	19	1.1k 1.0×	1.1k 1.1×	608 0.7×	191 0.6×	131 0.6×	40	2.2k
Yong Lu United States	24	1.3k 1.1×	1.0k 1.0×	949 1.0×	275 0.9×	170 0.7×	53	2.6k

Countries citing papers authored by David Y. Oh

Since Specialization

Citations

This map shows the geographic impact of David Y. Oh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Y. Oh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Y. Oh more than expected).

Fields of papers citing papers by David Y. Oh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Y. Oh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Y. Oh. The network helps show where David Y. Oh may publish in the future.

Co-authorship network of co-authors of David Y. Oh

This figure shows the co-authorship network connecting the top 25 collaborators of David Y. Oh. A scholar is included among the top collaborators of David Y. Oh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Y. Oh. David Y. Oh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Harrington, Kevin J., Stéphane Champiat, Joshua Brody, et al.. (2025). Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas. Clinical Cancer Research. 31(16). 3400–3411. 10 indexed citations

Montauti, Elena, David Y. Oh, & Lawrence Fong. (2024). CD4+ T cells in antitumor immunity. Trends in cancer. 10(10). 969–985. 40 indexed citations

Oh, David Y., Marcela Martínez-Prieto, Susan Haag, et al.. (2024). 50P Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies. Immuno-Oncology Technology. 24. 100861–100861. 2 indexed citations

Oh, David Y., Anthony Wong, Katsuto Shinohara, et al.. (2023). 862 TLR9 agonism promotes cytotoxic T cell persistence and myeloid remodeling when combined with radiation therapy and PD-1 blockade in oligometastatic prostate cancer patients. SHILAP Revista de lepidopterología. A961–A961. 1 indexed citations

Villa, Alessandro, Caleb Hwang, David Y. Oh, et al.. (2023). Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate Cancer. Clinical Genitourinary Cancer. 22(2). 380–384. 2 indexed citations

Zhao, Ning, André Luiz Lourenço, Yung-Hua Wang, et al.. (2021). In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET. ACS Central Science. 7(10). 1638–1649. 44 indexed citations

Bouquet, Jérôme, David Y. Oh, Timothy J. Looney, et al.. (2021). Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients. Cancer Immunology Immunotherapy. 70(7). 2095–2102. 17 indexed citations

Keenan, Bridget P., Katherine Van Loon, Anuradha Khilnani, et al.. (2021). Molecular and Radiological Features of Microsatellite Stable Colorectal Cancer Cases With Dramatic Responses to Immunotherapy. Anticancer Research. 41(6). 2985–2992. 7 indexed citations

Zhang, Li, Hai Yang, Jason Cham, et al.. (2020). Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T. Cancer Immunology Research. 8(12). 1496–1507. 17 indexed citations

10.

Looney, Timothy J., Geoffrey Lowman, Jeffrey M. Conroy, et al.. (2020). TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer. Frontiers in Immunology. 10. 2985–2985. 35 indexed citations

11.

Oh, David Y., Serena S. Kwek, Siddharth S. Raju, et al.. (2020). Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell. 181(7). 1612–1625.e13. 464 indexed citations breakdown →

12.

Hammami, Muhammad B., Ryan M. Gill, Nikhil R. Thiruvengadam, et al.. (2019). Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin. Digestive Diseases and Sciences. 64(3). 685–688.

13.

Hagihara, Katsunobu, Li Zhang, David Y. Oh, et al.. (2018). Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer. OncoImmunology. 8(1). e1486953–e1486953. 29 indexed citations

14.

Oh, David Y., Jason Cham, Li Zhang, et al.. (2016). Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire. Cancer Research. 77(6). 1322–1330. 173 indexed citations

15.

Oh, David Y., Alan P. Venook, & Lawrence Fong. (2015). On the Verge: Immunotherapy for Colorectal Carcinoma. Journal of the National Comprehensive Cancer Network. 13(8). 970–978. 11 indexed citations

16.

Bhakta, Nirav R., David Y. Oh, & Richard S. Lewis. (2005). Calcium oscillations regulate thymocyte motility during positive selection in the three-dimensional thymic environment. Nature Immunology. 6(2). 143–151. 202 indexed citations

17.

Dulai, Gareth S., Paul G Shekelle, Dennis M. Jensen, et al.. (2005). Dysplasia and Risk of Further Neoplastic Progression in a Regional Veterans Administration Barrett's Cohort. The American Journal of Gastroenterology. 100(4). 775–783. 80 indexed citations

18.

Fan, Zusen, Paul J. Beresford, David Y. Oh, Dong Zhang, & Judy Lieberman. (2003). Tumor Suppressor NM23-H1 Is a Granzyme A-Activated DNase during CTL-Mediated Apoptosis, and the Nucleosome Assembly Protein SET Is Its Inhibitor. Cell. 115(2). 241–241. 17 indexed citations

19.

Beresford, Paul J., Dong Zhang, David Y. Oh, et al.. (2001). Granzyme A Activates an Endoplasmic Reticulum-associated Caspase-independent Nuclease to Induce Single-stranded DNA Nicks. Journal of Biological Chemistry. 276(46). 43285–43293. 137 indexed citations

20.

Gommerman, Jennifer L., David Y. Oh, Xiaoning Zhou, et al.. (2000). A Role for CD21/CD35 and CD19 in Responses to Acute Septic Peritonitis: A Potential Mechanism for Mast Cell Activation. The Journal of Immunology. 165(12). 6915–6921. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact